Next, Tiba Alsagir, a clinical pharmacist from Baptist Health South Florida, spoke about her presentation on developing a precision approach for mitigating CAR-T cell therapy toxicity.

The inspiration for that particular talk was actually the data that's emerging on what biomarkers to look for and how that determines what toxicities are actually going to emerge and how we pull the trigger.

And there is a 2026 ASTCT consensus guidance document that goes over what those biomarkers and what we should be looking at.

So they stratify it into something that we must have or should have, can have, and nice to have.

So it's nice to have that information.

consensus guidance to guide us in terms of what we should really be doing as routine testing and should be readily available versus things that should be tested just to keep for research purposes.

and start your treatment for ICHS and escalate therapy.

Another thing that I did not mention is, you know, the difference between CRS and ICANS versus those delayed neurotoxicities or non-conventional toxicities is with CRS and ICANS, we're seeing more inflammatory markers and cytokines.